

## AMENDMENTS TO THE CLAIMS:

The following is a complete list of the pending claims.

1. (Cancelled)
2. (Currently amended) A pharmaceutical composition comprising one or more isolated peptides selected from the following:
  - a) a peptide ~~having the amino acid sequence~~ consisting of SEQ ID NO:30, wherein the ~~N-terminal amino acid residue comprises an~~ peptide's N-terminal chemical moiety is an amino group and the ~~C-terminal amino acid residue comprises a~~ peptide's C-terminal chemical moiety is a carboxyl group; or
  - b) a peptide ~~having the sequence~~ consisting of SEQ ID NO:30, ~~wherein the chemical moiety at the peptide's N-terminus is not an amino group or wherein the chemical moiety at the peptide's C-terminus is not a carboxyl group,~~ wherein the peptide's N-terminal chemical moiety is selected from the group consisting of ~~[[:]]~~ an acetyl group, a hydrophobic group, a carbobenzoxyl group, a dansyl group, a t-butyloxycarbonyl group, and a macromolecular ~~carrier~~ group; ~~[[,]]~~ or wherein the peptide's C-terminal chemical moiety is selected from the group consisting of an amido group, a hydrophobic group, a t-butyloxycarbonyl group and a macromolecular group~~[[:]]~~
  - ~~e) a peptide having the sequence of SEQ ID NO:30, wherein at least one bond linking adjacent amino acid residues is a non-peptide bond;~~
  - ~~d) a peptide having the sequence of SEQ ID NO:30, wherein at least one amino acid residue is in the D-isomer configuration;~~
  - ~~e) a peptide as in part "a)" or "b)" except that at least one amino acid has been substituted by a different amino acid; or~~
  - ~~f) a functional fragment of a peptide as set out in any of parts "a)" to "e)", having at least 3 contiguous amino acids of SEQ ID NO:30.~~

3-14. (Cancelled)

15. (Currently amended) The composition of claim 2 wherein the selected peptide ~~comprises~~ consists of SEQ ID NO:30, wherein the peptide's N-terminal moiety is an amino group and the peptide's C-terminal moiety is a carboxyl group.
16. (Currently amended) The composition of claim ~~[[15]]~~ 2 wherein the selected peptide consists of SEQ ID NO:30, wherein the peptide's N-terminal chemical moiety is an acetyl group, a hydrophobic group, a carbobenzoxy group, a dansyl group, a t-butyloxycarbonyl group, or a macromolecular ~~carrier~~ group; or wherein the peptide's C-terminal chemical moiety is an amido group, a hydrophobic group, a t-butyloxycarbonyl group or a macromolecular group.
17. (Currently amended) The composition of claim ~~[[15]]~~ 16 wherein the N-terminal chemical moiety is a macromolecular ~~carrier~~ group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate; or wherein the C-terminal chemical moiety is a macromolecular ~~carrier~~ group selected from a lipid conjugate, polyethylene glycol, or a carbohydrate.
- 18-26. (Cancelled)
27. (Withdrawn – Currently amended) A method of treating or preventing a Flavivirus infection comprising administering to the patient an effective amount of a pharmaceutical composition according to claim ~~[[1]]~~ 15.
28. (Withdrawn) A method of treating or preventing a Flavivirus infection comprising administering to the patient an effective amount of a pharmaceutical composition according to claim 2.
- 29-31. (Cancelled)

32. (New – Withdrawn) The method of claim 27, wherein the Flavivirus is Dengue virus.
33. (New – Withdrawn) The method of claim 28, wherein the Flavivirus is Dengue virus.